CagriSema is an investigational fixed‑dose combination of cagrilintide (a long‑acting amylin analogue) and semaglutide (a GLP‑1 receptor agonist) in a once‑weekly injection. It is being developed by Novo Nordisk to address both overweight/obesity and type 2 diabetes.
